Barrett’s metaplasia (BM) is a common pre-malignant condition with unknown population prevalence, but an increasing endoscopic incidence. BM develops in the context of gastro-oesophageal reflux and is a major risk factor for oesophageal adenocarcinoma, which develops from BM via a metaplasia–dysplasia–carcinoma pathway. Current treatment strategies aim to prevent the progression through this pathway with drug regimes and detect dysplasia early via endoscopic surveillance. Multiple imaging modalities and adjuncts have been employed to detect dysplastic epithelium in BM, including high-definition endoscopy, confocal endomicroscopy, narrow band imaging, chromoendoscopy and autofluorescence. Historically, oesophagectomy was the only potentially curative treatment option for oesophageal adenocarcinoma in the context of BM, but the last 10 years have seen a dramatic increase in the use of endoscopic resection and ablation technologies. Endoscopic mucosal resection, photodynamic therapy and radiofrequency ablation can be considered for treatment of high-grade dysplasia and early oesophageal adenocarcinoma.
Share this Article
Related Content In Gastrointestinal Cancers
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 1, 2023
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features some of the recent key developments in oncological and haematological disease. The journal opens with an expert interview with Linda Martin on a new fluorescent imaging agent for lung cancer detection. Screening using conventional methods is challenging but the results from the […]
Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma
touchREVIEWS in Oncology & Haematology. 2023;19(1):17-21 DOI: https://doi.org/10.17925/OHR.2023.19.1.17
Oesophageal cancer (OC) is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide,1 with approximately 604,000 new cases in 2020.2 OC has two main histological subtypes: oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC). Worldwide, OSCC accounts for approximately 90% of all cases of oesophageal carcinoma and OAC for approximately 10%.3 OSCC is the most common subtype in East Asia and East Africa, and rates of OAC are […]
Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(1):22-26 DOI: https://doi.org/10.17925/OHR.2023.19.1.22
Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree and are classified into cholangiocarcinoma (CCA) and gallbladder cancer. BTC is an aggressive and rare epithelial malignancy that is usually diagnosed at an advanced stage with few effective therapeutic options.1 CCA is divided into extrahepatic and intrahepatic cholangiocarcinoma, with the extrahepatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!